Evaluating the Toxicity Profile of Parsaclisib in Mantle Cell Lymphoma
Amitkumar Mehta, MD, discusses the toxicity profile of parsaclisib in the phase 2 CITADEL-205 clinical trial of relapsed/refractory mantle cell lymphoma.